Publications by authors named "J J Koldenhof"

Article Synopsis
  • The Utrecht Symptom Diary (USD) is a validated tool for assessing symptoms in cancer patients, incorporating 11 main symptoms and additional ones specific to those undergoing chemotherapy or targeted therapy.
  • A study conducted between 2012 and 2021 analyzed the effectiveness of these added symptoms in adult cancer patients receiving treatment, using a longitudinal cohort approach.
  • Results indicated that most added items were relevant and valid for this patient group, with all but one item (oral pain) demonstrating acceptable validity, highlighting the tool's comprehensive nature for monitoring treatment-related symptoms.
View Article and Find Full Text PDF

Uric acid induces radical oxygen species formation, endothelial inflammation, and endothelial dysfunction which contributes to the progression of atherosclerosis. Febuxostat inhibits BCRP- and allopurinol stimulates MRP4-mediated uric acid efflux in human embryonic kidney cells. We hypothesized that endothelial cells express uric acid transporters that regulate intracellular uric acid concentration and that modulation of these transporters by febuxostat and allopurinol contributes to their different impact on cardiovascular mortality.

View Article and Find Full Text PDF
Article Synopsis
  • People with advanced cancer are surviving longer but feel stuck between being a patient and feeling healthy.
  • A study talked to 17 people with stable cancer to learn how they cope with their situation.
  • They found that using strategies like getting support from friends and family and living in the moment helps them feel more in control and balanced.
View Article and Find Full Text PDF

Purpose: The introduction of immunotherapy and targeted therapy has drastically improved the life expectancy of patients with advanced cancer. Despite improved survival, obtaining long-term response can be highly distressing and comes with uncertainties that affect several life domains. The aim of this study is to gain a deeper understanding of long-term responders' lived experiences with obtaining long-term response to immunotherapy or targeted therapy.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) that range from mild to life-threatening. Age itself does not seem to be a predictor for the occurrence of irAEs. It is unknown whether frailty plays a role in the occurrence of irAEs.

View Article and Find Full Text PDF